Corient Capital Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Corient Capital Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$216K	Hold	2,707	–	–	0.02%	592
2022 Q2	$216K	Sell	2,707 -400	-13%	-$37.9K	0.02%	606
2022 Q1	$327K	Buy	3,107 +33	+1%	+$3.22K	0.02%	509
2021 Q4	$331K	Buy	3,074 +87	+3%	+$9.49K	0.02%	482
2021 Q3	$327K	Buy	2,987 +345	+13%	+$35.8K	0.02%	468
2021 Q2	$247K	Buy	2,642 +469	+22%	+$43.2K	0.02%	555
2021 Q1	$200K	Buy	+2,173	New	+$183K	0.02%	572

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Corient Capital Partners's HZNP Position: Q3 2022 in Review

Corient Capital Partners held its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) position steady in Q3 2022 at 2,707 shares worth $216K. The position accounts for 0.02% of the portfolio, ranked #592.

Corient Capital Partners first reported a position in HZNP in Q1 2021 and has held it in 7 quarters since. The position peaked at $331K in Q4 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Corient Capital Partners held 2,707 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $216K as of Q3 2022.
Corient Capital Partners left its Horizon Therapeutics Public Limited Company Ordinary Shares share count unchanged in Q3 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.02% of Corient Capital Partners's portfolio in Q3 2022, its #592 holding.
Corient Capital Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and has held it in 7 quarters since.
Corient Capital Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $331K in Q4 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.